CASI Pharmaceuticals, Inc. (CASI)

Market Cap	32.70M
Revenue (ttm)	33.88M
Net Income (ttm)	-26.96M
Shares Out	13.40M
EPS (ttm)	-2.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,070
Open	2.510
Previous Close	2.510
Day's Range	2.440 - 2.580
52-Week Range	1.850 - 8.480
Beta	0.33
Analysts	Strong Buy
Price Target	12.00 (+391.8%)
Earnings Date	May 15, 2024

About CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 1996
• Employees: 176
• Stock Exchange: NASDAQ
• Ticker Symbol: CASI

Financial Performance

In 2023, CASI's revenue was $33.88 million, a decrease of -21.41% compared to the previous year's $43.11 million. Losses were -$26.96 million, -34.27% less than in 2022.

Analyst Forecast

According to one analyst, the rating for CASI stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target

$12.0

(391.80% upside)

Analyst Consensus: Strong Buy